152 related articles for article (PubMed ID: 14612946)
1. Considerations on development, validation, application, and quality control of immuno(metric) biomarker assays in clinical cancer research: an EORTC-NCI working group report.
Sweep FC; Fritsche HA; Gion M; Klee GG; Schmitt M;
Int J Oncol; 2003 Dec; 23(6):1715-26. PubMed ID: 14612946
[TBL] [Abstract][Full Text] [Related]
2. Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer.
Schmitt M; Harbeck N; Daidone MG; Brynner N; Duffy MJ; Foekens JA; Sweep FC
Int J Oncol; 2004 Nov; 25(5):1397-406. PubMed ID: 15492831
[TBL] [Abstract][Full Text] [Related]
3. [Diagnostic kits in parasitology: which controls?].
Rossi P
Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705
[TBL] [Abstract][Full Text] [Related]
4. Research-design issues in cancer-symptom-management trials using complementary and alternative medicine: lessons from the National Cancer Institute Community Clinical Oncology Program experience.
Buchanan DR; White JD; O'Mara AM; Kelaghan JW; Smith WB; Minasian LM
J Clin Oncol; 2005 Sep; 23(27):6682-9. PubMed ID: 16170176
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers in translational research: focus on discovery, development and translation of protein biomarkers to clinical immunoassays.
Rai AJ
Expert Rev Mol Diagn; 2007 Sep; 7(5):545-53. PubMed ID: 17892363
[TBL] [Abstract][Full Text] [Related]
6. AACR-FDA-NCI cancer biomarkers collaborative.
Yu LR; Veenstra TD
Expert Rev Mol Diagn; 2007 Sep; 7(5):507-9. PubMed ID: 17892359
[TBL] [Abstract][Full Text] [Related]
7. Insights in the application of research-grade diagnostic kits for biomarker assessments in support of clinical drug development: bioanalysis of circulating concentrations of soluble receptor activator of nuclear factor kappaB ligand.
Bowsher RR; Sailstad JM
J Pharm Biomed Anal; 2008 Dec; 48(5):1282-9. PubMed ID: 18977625
[TBL] [Abstract][Full Text] [Related]
8. Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies.
Valentin MA; Ma S; Zhao A; Legay F; Avrameas A
J Pharm Biomed Anal; 2011 Jul; 55(5):869-77. PubMed ID: 21530130
[TBL] [Abstract][Full Text] [Related]
9. External quality assessment of assays for hormones and tumor markers in Italian laboratories.
Zucchelli GC; Pilo A; Malvano R; Signorini C; Bolelli GF; Albertini A
Ann Ist Super Sanita; 1991; 27(3):479-86. PubMed ID: 1809068
[TBL] [Abstract][Full Text] [Related]
10. Validation of assays for use with combination vaccines.
Klein J; Capen R; Mancinelli R; Robinett R; Pietrobon PJ; Quinn J; Schofield T
Biologicals; 1999 Mar; 27(1):35-41. PubMed ID: 10441401
[TBL] [Abstract][Full Text] [Related]
11. A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturers' laboratories.
Fritzler MJ; Wiik A; Tan EM; Smolen JS; McDougal JS; Chan EK; Gordon TP; Hardin JA; Kalden JR; Lahita RG; Maini RN; Reeves WH; Rothfield NF; Takasaki Y; Wilson M; Byrd MG; Slivka L; Koziol JA
J Rheumatol; 2003 Nov; 30(11):2374-81. PubMed ID: 14677180
[TBL] [Abstract][Full Text] [Related]
12. [The external quality assessment for Mycobacterium tuberculosis drug susceptibility testing by proficiency testing panel to the commercial laboratories].
Mitarai S;
Kekkaku; 2005 Apr; 80(4):349-58. PubMed ID: 15991600
[TBL] [Abstract][Full Text] [Related]
13. Quality control of biomarker measurement in epidemiology.
Gompertz D
IARC Sci Publ; 1997; (142):215-22. PubMed ID: 9354921
[TBL] [Abstract][Full Text] [Related]
14. The systematic monitoring of transfusion microbiology test kit performance.
Nightingale MJ; Ramskill S; Newham J; Kitchen A; Bukasa A; Wenham D; Reeves I
Transfus Med; 2007 Oct; 17(5):404-12. PubMed ID: 17903142
[TBL] [Abstract][Full Text] [Related]
15. Translational crossroads for biomarkers.
Bast RC; Lilja H; Urban N; Rimm DL; Fritsche H; Gray J; Veltri R; Klee G; Allen A; Kim N; Gutman S; Rubin MA; Hruszkewycz A
Clin Cancer Res; 2005 Sep; 11(17):6103-8. PubMed ID: 16144908
[TBL] [Abstract][Full Text] [Related]
16. Quality assurance/quality control of foot and mouth disease solid phase competition enzyme-linked immunosorbent assay--Part II. Quality control: comparison of two charting methods to monitor assay performance.
Goris N; De Clercq K
Rev Sci Tech; 2005 Dec; 24(3):1005-16. PubMed ID: 16642771
[TBL] [Abstract][Full Text] [Related]
17. The importance of analytical quality specifications for biomarker assays currently used in acute cardiac care.
Panteghini M
Acute Card Care; 2006; 8(3):133-8. PubMed ID: 17012126
[TBL] [Abstract][Full Text] [Related]
18. Challenges of cancer biomarker profiling.
Bensalah K; Montorsi F; Shariat SF
Eur Urol; 2007 Dec; 52(6):1601-9. PubMed ID: 17919807
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of the results of the SEIMC External Quality Control Program for HIV-1 and HCV viral loads, 2007].
; Orta Mira N; Guna Serrano Mdel R; Latorre Martínez JC; Ovies MR; Pérez JL; Gimeno Cardona C
Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 13():8-13. PubMed ID: 19100161
[TBL] [Abstract][Full Text] [Related]
20. What is the future of oncology? National Cancer Institute initiatives to improve research, development, and implementation in cancer prevention and treatment.
Hawk E; Viner JL
Semin Oncol; 2006 Dec; 33(6 Suppl 11):S6-9. PubMed ID: 17178278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
